Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4555854 | 0.73 | — | — | |
| SCHEMBL29161382 | 0.72 | MAPT (0.54) | MAPTKMT2AALDH1A1MEN1POLB | |
| SCHEMBL1649691 | 0.71 | MAPT (0.38) | MAPTKMT2AALDH1A1MEN1POLB | |
| SCHEMBL30101244 | 0.68 | ALDH1A1 (0.31) | MAPTKMT2AALDH1A1MEN1POLB | |
| SCHEMBL9666118 | 0.68 | MAPT (0.38) | MAPTKMT2AALDH1A1MEN1POLB | |
| SCHEMBL6278365 | 0.68 | MAPT (0.35) | MAPTKMT2AALDH1A1MEN1POLB | |
| SCHEMBL1924981 | 0.68 | MAPT (0.38) | MAPTKMT2AALDH1A1MEN1POLB | |
| SCHEMBL8525118 | 0.68 | MAPT (0.35) | MAPTKMT2AALDH1A1MEN1POLB | |
| SCHEMBL7329297 | 0.67 | MAPT (0.35) | MAPTKMT2AALDH1A1MEN1POLB | |
| SCHEMBL5734376 | 0.66 | MAPT (0.32) | MAPTKMT2AALDH1A1MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1239882-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | claimed |
| WO-2001045685-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | claimed |
| EP-0306323-A2 | Lactam derivatives | GLAXO GROUP LIMITED (GB) | 1989-03-08 | — | — | EP | claimed |
| EP-4540245-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LigaChem Biosciences Inc. (KR) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023242631-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-12-21 | — | — | WO | disclosed |
| EP-3148543-A2 | SMALL MOLECULE TRANSCRIPTION MODULATORS OF BROMODOMAINS | Icahn School of Medicine at Mount Sinai (US) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015184257-A2 | SMALL MOLECULE TRANSCRIPTION MODULATORS OF BROMODOMAINS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-12-03 | — | — | WO | disclosed |
| US-9181240-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9096591-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034880-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| EP-0481254-A2 | 2-(4-Piperidinyl)-1H-pyrido[4,3-b]indol-1 ones and related compounds, intermediates and a process for their preparation | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-04-22 | — | — | EP | disclosed |
| US-5102889-A | For treating psychosis | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1992-04-07 | — | — | US | disclosed |
| EP-0411901-A2 | Treatment of conditions involving excessive eating | GLAXO GROUP LIMITED (GB) | 1991-02-06 | — | — | EP | disclosed |
| EP-0385721-A2 | Process for the preparation of lactam derivatives | GLAXO GROUP LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0357415-A2 | Use of serotonin antagonists in the treatment of cognitive disorders | GLAXO GROUP LIMITED (GB) | 1990-03-07 | — | — | EP | disclosed |
| EP-0357416-A2 | Use of serotonin antagonists in the treatment of drug addiction | GLAXO GROUP LIMITED (GB) | 1990-03-07 | — | — | EP | disclosed |
| EP-0357414-A2 | Use of serotonin antagonists in the treatment of depression | GLAXO GROUP LIMITED (GB) | 1990-03-07 | — | — | EP | disclosed |
| EP-0353983-A2 | Lactam derivatives | GLAXO GROUP LIMITED (GB) | 1990-02-07 | — | — | EP | disclosed |
| EP-0306323-A2 | Lactam derivatives | GLAXO GROUP LIMITED (GB) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | MAPT 252/4885KMT2A 434/4885ALDH1A1 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.